Hodgkin lymphoma treatment with ABVD in the US and the EU: Neutropenia occurrence and impaired chemotherapy delivery

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Schwenkglenks, Matthias ^a   Pettengell, Ruth ^b   Szucs, Thomas D ^a   Culakova, Eva ^c   Lyman, Gary H ^c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; COLONY STIMULATING FACTOR; DACARBAZINE; DOXORUBICIN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG USE; EUROPEAN UNION; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; RISK ASSESSMENT; UNITED STATES; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COLONY-STIMULATING FACTORS; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; VINBLASTINE;

EID: 77955676367     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-27     Document Type: Article

References (20)

1. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial. DB Duggan GR Petroni JL Johnson JH Glick RI Fisher JM Connors JP Canellos BA Peterson, J Clin Oncol 2003 21 607 614 10.1200/JCO.2003.12.086 12586796
2. Treatment of Hodgkin lymphoma: the past, present, and future. AM Evens M Hutchings V Diehl, Nat Clin Pract Oncol 2008 5 543 556 10.1038/ncponc1186 18679394
3. Hodgkin's lymphoma: news from an old disease. JMM Raemaekers RWM van der Maazen, Neth J Med 2008 66 457 466 19075311
4. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. NM Kuderer DC Dale J Crawford LE Cosler GH Lyman, Cancer 2006 106 2258 2266 10.1002/cncr.21847 16575919
5. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. MS Aapro DA Cameron R Pettengell J Bohlius J Crawford M Ellis N Kearney GH Lyman VC Tjan-Heijnen J Walewski DC Weber C Zielinski European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party, Eur J Cancer 2006 42 2433 2453 10.1016/j.ejca.2006.05.002 16750358
6. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. J Crawford JC Dale GH Lyman, Cancer 2004 100 228 237 10.1002/cncr.11882 14716755
7. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. I Chirivella B Bermejo A Insa A Pérez-Fidalgo A Magro S Rosello E García-Garre P Martín A Bosch A Lluch, Breast Cancer Res Treat 2009 114 479 484 10.1007/s10549-008-0018-1 18463977
8. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. A Bosly D Bron A van Hoof R de Bock Z Berneman A Ferrant L Kaufman M Dauwe G Verhoef, Ann Haematol 2008 87 277 283 10.1007/s00277-007-0399-y
9. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. G Bonadonna P Valagussa A Moliterni M Zambetti C Brambilla, N Engl J Med 1995 332 901 906 10.1056/NEJM199504063321401 7877646
10. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. LW Kwak J Halpern RA Olshen SJ Horning, J Clin Oncol 1990 8 963 977 2348230
11. Impact of chemotherapy dose intensity on cancer patient outcomes. GH Lyman, J Natl Compr Canc Netw 2009 7 99 108 19176210
12. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. VK Chand BK Link JM Ritchie M Shannon JE Wooldridge, Leuk Lymphoma 2006 47 657 663 10.1080/10428190500353430 16690524
13. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Crawford DC Dale NM Kuderer E Culakova MS Poniewierski D Wolff GH Lyman, J Natl Compr Canc Netw 2008 6 109 118 18319047
14. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. R Pettengell M Schwenkglenks R Leonard A Bosly R Paridaens M Constenla T Szucs C Jackisch Impact of Neutropenia in Chemotherapy - European Study Group (INC-EU), Support Care Cancer 2008 16 1299 1309 10.1007/s00520-008-0430-4 18351398
15. Simplified calculation of body-surface area. RD Mosteller, N Eng J Med 1987 317 1098
16. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Cancer Therapy Evaluation Program, 2006 http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm#ctc-40 accessed 20 July 2010
17. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. DC Dale GC McCarter J Crawford GH Lyman, J Natl Compr Canc Netw 2003 1 440 454 19761076
18. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. AM Evens J Cilley T Ortiz M Gounder N Hou A Rademaker S Miyata K Catsaros C Augustyniak CL Bennett MS Tallman D Variakojis JN Winter LI Gordon, Br J Haematol 2007 137 545 552 10.1111/j.1365-2141.2007.06598.x 17459049
19. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. E Boleti GM Mead, Ann Oncol 2007 18 376 380 10.1093/annonc/mdl397 17071938
20. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. VK Chand BK Link JM Ritchie M Shannon JE Wooldridge, Leuk Lymphoma 2006 47 657 663 10.1080/10428190500353430 16690524